# Ipamorelin Effects, Side Effects & Safety: What the Research Shows > Ipamorelin effects people report and the cited safety cautions. Anecdotal community reports kept separate from mechanism-grounded, cited safety reasoning. ## Start here This page on ipamorelin effects covers two different things and keeps them apart. First, what people in research-use communities say it does for them, the good and the bad. Those are stories, not studies, and they are labeled that way. Second, who has a real reason to be careful, with each caution tied to a published study or a known biological mechanism. The short list: the most common reported upside is deeper sleep, often within a week or two. The most common reported downside is a brief facial flush right after injection. On the safety side, the genuinely useful context is that ipamorelin nudges the growth-hormone system, which touches blood sugar, fluid balance, and (in theory) cell growth, so people with diabetes, heart conditions, or a cancer history have specific reasons to be cautious. None of this is medical advice, and there are no doses anywhere on this page. ## What people report These are effects described by the research-use community. They are **anecdotal, not clinical evidence**: self-reported, unverified, with unknown dose and source, and not confirmed by controlled trials. They are collected here for honest context, never as proof that ipamorelin does any of these things. **Reported benefits** - **Deeper, more restorative sleep** (frequently reported). The single most-cited benefit. People describe falling asleep faster, sleeping more deeply, and waking more rested, often within one to two weeks of a pre-bed routine. - **Vivid dreams, especially early on** (frequently reported). More intense dreams in the first week or two, often read as a sign of more REM sleep, usually settling down afterward. - **Faster physical recovery and less post-training soreness** (frequently reported). Quicker bounce-back between sessions, less soreness, and a better subjective sense of joint and tissue recovery over weeks. - **A gradually leaner look** (occasionally reported). A slow shift toward leaner body composition, usually noticed from roughly week five to twelve, described as subtle rather than dramatic and heavily confounded by diet and training. **Reported adverse effects** - **Facial flushing and a head-rush after injection** (frequently reported). A warm flush across the face, neck, or chest about 5 to 15 minutes after injecting, lasting up to an hour, often compared to a niacin flush. - **Tingling or numbness in hands and feet** (occasionally reported). Transient tingling in fingers and feet, usually worst in the first few weeks and often blamed on fluid shifts. - **Mild water retention and puffiness** (occasionally reported). Brief puffiness in fingers, ankles, or face in the first few weeks, generally described as milder than with older peptides. - **Increased hunger after injection** (occasionally reported). Because ipamorelin acts on the hunger-hormone (ghrelin) receptor, some people notice more appetite in the hours after a dose, described as milder than with GHRP-6. - **Early fatigue, dizziness, or a "spacey" feeling** (occasionally reported). Transient lightheadedness or a weak, foggy feeling shortly after injecting, mostly in the early weeks. - **Injection-site irritation** (occasionally reported). Mild redness, itching, or swelling at the injection spot, usually clearing within a day or two. - **A fading response over months** (occasionally reported). Some users say the sleep and growth-hormone-related effects seem to dim after three to four months of continuous use, which is the rationale behind the on/off cycling discussed in forums. ## Safety & cautions These cautions are grounded in published mechanism and study data, and each is cited. Several are *theoretical* or *class-level*, meaning they follow from how the growth-hormone system works or from studies of related compounds, not from harm observed in an ipamorelin trial. Where that is the case, it is said plainly. **Active or recent cancer / proliferative conditions.** Growth hormone drives the liver to make IGF-1, and IGF-1 is a well-characterized mitogen, a signal that pushes cells to grow and survive. Ipamorelin's founding study showed potent growth-hormone release [1], and sustained growth-hormone signaling raises IGF-1 over time. The theoretical concern is that chronically raising growth-hormone pulses could feed proliferative activity in an existing or hidden tumor [4]. No ipamorelin cancer or tumor-promotion study exists in humans; this caution is purely mechanistic, not derived from observed cancer events in any ipamorelin study. **Diabetes, impaired glucose tolerance, or insulin resistance.** Growth hormone is a counter-regulatory hormone that lowers insulin sensitivity and can raise fasting glucose. On top of that, ipamorelin has a separate, growth-hormone-independent effect directly on the pancreas: pancreatic tissue from normal and diabetic rats released insulin in response to ipamorelin (at 10^-12 to 10^-6 M) through calcium-channel and adrenergic/cholinergic pathways [12]. These two opposite influences make the net effect on blood sugar unpredictable in someone whose glucose control is already off. No human glucose data exist for ipamorelin at research-use exposures [1]. **Active cardiovascular disease, heart failure, or significant edema.** Growth-hormone excess (as in the disease acromegaly) is linked to salt and water retention and an enlarged heart, so raising growth-hormone pulses chronically could worsen fluid-overload states. Separately, a 28-day study of GSK894281, a different agonist of the same ghrelin (GHS-R1a) receptor, found dose-dependent heart-muscle degeneration and necrosis in rats [6]. Ipamorelin itself was not the compound tested, and no long-duration cardiovascular safety study of ipamorelin exists in any species. This is a class-level signal that makes chronic dosing a concern for anyone with underlying heart vulnerability [6]. **Appetite dysregulation, weight-gain susceptibility, or adiposity-related conditions.** Ghrelin-receptor agonists switch on brain appetite centers and drive feeding [14]. Ipamorelin additionally stimulated adiposity and raised leptin in both growth-hormone-deficient and normal mice after two weeks of dosing, showing that part of its body-composition effect is independent of growth hormone and works through direct receptor signaling [13]. Anyone for whom extra appetite or fat gain would be harmful should know the ghrelin-agonist mechanism carries an orexigenic (appetite-raising) and adipogenic signal that selectivity does not cancel out. **Unknown long-term human safety; unverified purity of research material.** The only controlled human dataset is the single Phase 2 RCT in a short, up-to-7-day window [3], plus the acute single-dose human PK study in eight volunteers per dose [2]. No Phase 3 trial has run; no long-term human safety database exists. The dominant route in off-label use is subcutaneous self-injection, which has no published human safety or pharmacokinetic characterization. Research-grade material from unregulated suppliers is also not subject to pharmaceutical quality assurance, so purity, identity, and sterility are unverified. These are documented gaps, not hypotheticals [3]. **A note on the selectivity advantage.** Unlike older growth-hormone-releasing peptides such as GHRP-6 and GHRP-2, ipamorelin does not meaningfully raise cortisol, ACTH, or prolactin even at doses more than 200-fold above its growth-hormone ED50, which is its defining feature [1]. That removes one concern that applies to less selective peptides, adrenal stimulation and high prolactin. It is a relative advantage grounded in the founding study, not a claim that ipamorelin has no off-target effects [1]. ## Is cjc-1295 ipamorelin safe There is no completed safety trial of the CJC-1295 plus ipamorelin combination for any outcome; what exists is single-agent pharmacology for each peptide [3]. Ipamorelin's selectivity for growth hormone over cortisol and prolactin is well-documented [1], but the class carries a cardiotoxicity signal seen in a 28-day rat study of a related ghrelin-receptor agonist [6], and long-term human data are absent [3]. The honest answer is that the combination's safety is uncharacterized in controlled human trials. ## Is ipamorelin fda approved No. Ipamorelin has never been approved as a drug by the FDA, EMA, or any regulatory body, for any indication. Its only Phase 2 trial, for postoperative ileus, missed its primary endpoint [3]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list and reviewed it at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting, restricting compounding-pharmacy access. It is also banned in sport at all times under WADA category S2. It is sold only as a research chemical. ## Then and now Ipamorelin (development code NNC 26-0161) was created by Novo Nordisk in the 1990s as the first highly selective growth-hormone secretagogue, characterized in 1998 by Raun and colleagues as a pentapeptide that releases growth hormone without raising cortisol [1]. Its human pharmacokinetics were described in 1999 [2]. It was later advanced for postoperative ileus, the only indication that reached Phase 2; that 2014 trial missed its primary endpoint and no further development followed [3]. Ipamorelin was never approved as a drug by any authority and has no historical prescribing indication, so there is no "then" in which it was a marketed medicine, only a research history that continues today. --- Newest-studies-first, every figure pinned to its source: an independent ipamorelin reading desk, never a clinic, a prescription, or a checkout.